drugset / Trial / NCT00241111

Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis

NCT00241111

Phase 4 Completed 148 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to determine effectiveness and safety of zoledronic acid and whether it has a pharmaco-economic impact in prostate cancer with bone metastasis.

Timeline

Start
2003-09
Primary completion
2006-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified